- TB cases in the US decreased from 1953 to 1984 but increased 20% from 1985 to 1992, with 25,313 cases reported in 1993. Since then, cases have declined steadily. - Factors contributing to the increase included the HIV epidemic, increased immigration from high-prevalence countries, transmission in congregate settings like prisons and nursing homes, and deterioration of public health infrastructure. - TB is caused by Mycobacterium tuberculosis bacteria and is spread through airborne particles inhaled by an uninfected person during prolonged contact with an active case.

1. Fundamentals of
Tuberculosis (TB)
name : Avinash k
1

2. TB in the United States
• From 1953 to 1984, reported cases
decreased by approximately 5.6% each
year
• From 1985 to 1992, reported cases
increased by 20%
• 25,313 cases reported in 1993
• Since 1993, cases are steadily declining
2

3. Factors Contributing to the
Increase in TB Cases
• HIV epidemic
• Increased immigration from high-
prevalence countries
• Transmission of TB in congregate settings
(e.g., correctional facilities, long term care)
• Deterioration of the public health care
infrastructure
3

4. Transmission and
Pathogenesis of TB
• Caused by Mycobacterium tuberculosis (M.
tuberculosis)
• Spread person to person through airborne particles
that contain M. tuberculosis, called droplet nuclei
• Transmission occurs when an infectious person
coughs, sneezes, laughs, or sings
• Prolonged contact needed for transmission
• 10% of infected persons will develop TB disease at
some point in their lives
4

5. Sites of TB Disease
• Pulmonary TB occurs in the lungs
– 85% of all TB cases are pulmonary
• Extrapulmonary TB occurs in places other than the
lungs, including the:
– Larynx
– Lymph nodes
– Brain and spine
– Kidneys
– Bones and joints
• Miliary TB occurs when tubercle bacilli enter the
bloodstream and are carried to all parts of the body
5

6. Not Everyone Exposed
Becomes Infected
• Probability of transmission depends
on:
– Infectiousness
– Type of environment
– Length of exposure
• 10% of infected persons will develop
TB disease at some point in their lives
– 5% within 1-2 years
– 5% at some point in their lives
6

7. Persons at Risk for Developing
TB Disease
• Persons at high risk for developing TB
disease fall into 2 categories
– Those who have been recently infected
– Those with clinical conditions that increase
their risk of progressing from LTBI to TB
disease
7

8. Recent Infection as a
Risk Factor
Persons more likely to have been recently
infected include
• Close contacts to persons with infectious TB
• Skin test converters (within past 2 years)
• Recent immigrants from TB-endemic areas
(within 5 years of arrival to the U.S.)
• Children ≤ 5 years with a positive TST
• Residents and employees of high-risk
congregate settings (e.g. correctional facilities,
homeless shelters, healthcare facilities)
8

9. Increased Risk for Progression to
TB Disease
Persons more likely to progress from LTBI to TB
disease include
• HIV infected persons
• Those with history of prior, untreated TB
• Underweight or malnourished persons
• Injection drug use
• Those receiving TNF-α antagonists for treatment
of rheumatoid arthritis or Crohn’s disease
• Certain medical conditions
9

10. Latent TB Infection (LTBI)
• Occurs when person breathes in bacteria
and it reaches the air sacs (alveoli) of lung
• Immune system keeps bacilli contained
and under control
• Person is not infectious and has no
symptoms
10

11. TB Disease
• Occurs when immune system cannot
keep bacilli contained
• Bacilli begin to multiply rapidly
• Person develops TB symptoms
11

12. LTBI vs. TB Disease
LTBI TB Disease
Tubercle bacilli in the body
TST or QFT-Gold® result usually positive
Chest x-ray usually normal Chest x-ray usually abnormal
Sputum smears and cultures
negative
Symptoms smears and cultures
positive
No symptoms Symptoms such as cough, fever,
weight, loss
Not infectious Often infectious before treatment
Not a case of TB A case of TB
12

13. Targeted Testing
• Detects persons with LTBI who would
benefit from treatment
• De-emphasize testing of groups of people
who are not at risk (mass screening)
• Consider using a risk assessment tool
• Testing should be done only if there is an
intent to treat
• Can help reduce the waste of resources
and prevent unnecessary treatment
13

14. Groups to Target with the
Tuberculin Skin Test
• Persons with or at risk for HIV infection
• Close contacts of persons with infectious TB
• Persons with certain medical conditions
• Injection drug users
• Foreign-born persons from areas where TB is common
• Medically underserved, low-income populations
• Residents of high-risk congregate settings
• Locally identified high-prevalence groups
14

15. Administering the TST
• Use Mantoux tuberculin skin test
• 0.1 mL of 5-TU of purified protein derivative
(PPD) solution injected intradermally
• Use a 27 gauge needle
• Produce a wheal that is 6-10mm in
diameter
15

16. Reading the TST
• Read within 48-72 hours
• Measure induration, not erythema
• Positive reactions can be measured
accurately for up to 7 days
• Negative reactions can be read
accurately for only 72 hours
16

17. TST Interpretation - 1
5 mm of induration is positive in:
– HIV-infected persons
– Close contacts to an infectious TB case
– Persons who have chest x-ray findings
consistent with prior untreated TB
– Organ transplant recipients
– Persons who are immunosuppressed (e.g.,
those taking the equivalent of >15 mg/d of
prednisone for 1 month or those taking TNF-α
antagonists)
17

18. TST Interpretation - 2
10 mm induration is positive in:
– Recent immigrants (within last 5 years) from a
high-prevalence country
– Injection drug users
– Persons with other high-risk medical conditions
– Residents or employees of high-risk congregate
settings
– Mycobacteriology laboratory personnel
– Children < 4 years of age; infants, children, and
adolescents exposed to adults at high risk
18

19. TST Interpretation - 3
15 mm induration is positive in:
• Persons with no known risk factors for
TB
19

20. Recording TST Results
• Record results in millimeters of induration,
not “negative” or “positive”
• Only trained healthcare professionals
should read and interpret TST results
20

21. False Positive TST Reactions
• Nontuberculous mycobacteria
– Reactions are usually ≤10mm of induration
• BCG vaccination
– Reactivity in BCG vaccine recipients generally wanes
over time
– Positive TST results is likely due to TB infection if risk
factors are present
– BCG-vaccinated persons with positive TST result
should be evaluated for treatment of LTBI
– QFT is able to distinguish M.tb from other
mycobacteria and BCG vaccine
21

22. False Negative TST Reactions
• Anergy, or inability to react to TST
because of weakened immune system
• Recent TB infection (2-10 weeks after
exposure)
• Very young age (newborns)
• Recent live-virus vaccination can
temporarily suppress TST reactivity
• Poor TST administration technique (too
shallow or too deep, or wheal is too small)
22

23. Boosting
• Some people with history of LTBI lose their
ability to react to tuberculin (immune
system “forgets” how to react to TB-like
substance, i.e., PPD)
• Initial TST may stimulate (boost) the ability
to react to tuberculin
• Positive reactions to subsequent tests may
be misinterpreted as new infections rather
than “boosted” reactions
23

24. Two-Step Testing - 1
• A strategy for differentiating between
boosted reactions and reactions caused
by recent TB infection
• Use two-step testing for initial (baseline)
skin testing of adults who will be re-tested
periodically
• 2nd skin test given 1-3 weeks after
baseline
24

25. Two-Step Testing - 2
• If the 1st TST is positive, consider the
person infected
• If the 1st TST is negative, administer 2nd
TST in 1-3 weeks
• If the 2nd TST is positive, consider the
person infected
• If the 2nd TST is negative, consider the
person uninfected at baseline
25

26. Infectiousness - 1
• Patients should be considered infectious if they:
– Are undergoing cough-inducing procedures
– Have sputum smears positive for acid-fast bacilli
(AFB) and:
• Are not receiving treatment
• Have just started treatment, or
• Have a poor clinical or bacterial response to
treatment
– Have cavitary disease
• Extrapulmonary TB patients are not infectious
26

27. Infectiousness - 2
• Patients are not considered infectious if
they meet all these criteria:
– Received adequate treatment for 2-3 weeks
– Favorable clinical response to treatment
– 3 consecutive negative sputum smears results
from sputum collected on different days
27

28. Techniques to Decrease TB
Transmission
• Instruct patient to:
– Cover mouth when coughing or sneezing
– Wear mask as instructed
– Open windows to assure proper ventilation
– Do not go to work or school until instructed by
physician
– Avoid public places
– Limit visitors
– Maintain home or hospital isolation as ordered
28

29. Evaluation for TB
• Medical history
• Physical examination
• Mantoux tuberculin skin test
• Chest x-ray
• Bacteriologic exam (smear and culture)
29

30. Symptoms of TB
• Productive prolonged cough*
• Chest pain*
• Hemoptysis*
• Fever and chills
• Night sweats
• Fatigue
• Loss of appetite
• Weight loss
*Commonly seen in cases of pulmonary TB
30

31. Chest x-Ray
• Obtain chest x-ray for patients with
positive TST results or with symptoms
suggestive of TB
• Abnormal chest x-ray, by itself, cannot
confirm the diagnosis of TB but can be
used in conjunction with other diagnostic
indicators
31

32. Sputum Collection
• Sputum specimens are essential to
confirm TB
– Specimens should be from lung secretions,
not saliva
• Collect 3 specimens on 3 different days
• Spontaneous morning sputum more
desirable than induced specimens
• Collect sputum before treatment is
initiated
32

33. Smear Examination
• Strongly consider TB in patients with
smears containing acid-fast bacilli (AFB)
• Use subsequent smear examinations to
assess patient’s infectiousness and
response to treatment
33

34. Culture
• Used to confirm diagnosis of TB
• Culture all specimens, even if smear
is negative
• Initial drug isolate should be used to
determine drug susceptibility
34

35. Treatment of Latent TB Infection
• Daily Isoniazid therapy for 9 months
– Monitor patients for signs and symptoms of
hepatitis and peripheral neuropathy
• Alternate regimen – Rifampin for 4 months
35

36. Treatment of TB Disease
• Include four 1st-line drugs in initial regimen
– Isoniazid (INH)
– Rifampin (RIF)
– Pyrazinamide (PZA)
– Ethambutol (EMB)
• Adjust regimen when drug susceptibility
results become available or if patient has
difficulty with any of the medications
• Never add a single drug to a failing regimen
• Promote adherence and ensure treatment
completion
36

37. Directly Observed Therapy (DOT)
• Health care worker watches patient
swallow each dose of medication
• DOT is the best way to ensure adherence
• Should be used with all intermittent
regimens
• Reduces relapse of TB disease and
acquired drug resistance
37

38. Clinical Monitoring
Instruct patients taking TB medications to
immediately report the following:
– Rash
– Nausea, loss of appetite, vomiting, abdominal
pain
– Persistently dark urine
– Fatigue or weakness
– Persistent numbness in hands or feet
38

39. Drug Resistance
• Primary - infection with a strain of M.
tuberculosis that is already resistant to one
or more drugs
• Acquired - infection with a strain of M.
tuberculosis that becomes drug resistant
due to inappropriate or inadequate
treatment
39

40. Barriers to Adherence
• Stigma
• Extensive duration of treatment
• Adverse reactions to medications
• Concerns of toxicity
• Lack of knowledge about TB and its
treatment
40

41. Improving Adherence
• Adherence is the responsibility of the
provider, not the patient and can be
ensured by:
– Patient education
– Directly observed therapy (DOT)
– Case management
– Incentives/enablers
41

42. Measures to Promote Adherence
• Develop an individualized treatment plan for
each patient
• Provide culturally and linguistically
appropriate care to patient
• Educate patient about TB, medication dosage,
and possible adverse reactions
• Use incentives and enablers to address
barriers
• Facilitate access to health and social services
42

43. Completion of Therapy
• Based on total number of doses
administered, not duration of treatment
• Extend or re-start if there were frequent or
prolonged interruptions
43

44. Meeting the Challenge
• Prevent TB by assessing risk factors
• If risk is present, perform TST
• If TST is positive, rule out active disease
• If active disease is ruled out, initiate
treatment for LTBI
• If treatment is initiated, ensure completion
44

45. Remember
“A decision to test is a decision to treat.”
45